ArticleClinical obesity2025
Exploring Metabolic Obesity Phenotypes and Atherosclerotic Cardiovascular Disease Risk in Arab Adults.
Article in Clinical obesity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring Metabolic Obesity Phenotypes and Atherosclerotic Cardiovascular Disease Risk in Arab Adults.Clinical obesity · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study investigates the 10-year atherosclerotic cardiovascular disease (ASCVD) risk in different metabolic obesity phenotypes in Saudi adults. A cohort of 5460 adults (aged 40-79) was categorised based on metabolic status, body mass index (BMI), and visceral adiposity index (VAI). Using the ASCVD Risk Estimator Plus, the 10-year risk scores were calculated and explored in different metabolic phenotypes. Females showed higher obesity prevalence, while males had a higher metabolically unhealthy phenotype prevalence. Despite being considered healthy by traditional metrics, individuals with Metabolically Healthy Obesity (MHO) exhibited significantly higher ASCVD risk scores compared to Metabolically Healthy Normal Weight (MHNW) counterparts (2.44 vs. 1.34 in females, p < 0.001; 9.60 vs. 6.72 in males, p = 0.008). When obesity was defined by BMI, in men, MHO showed a substantially higher age-adjusted odds ratio (OR) for greater ASCVD risk than MHNW (OR = 2.04, 95% CI 1.3-3.3, p = 0.003). However, when obesity was characterised by VAI rather than BMI, ASCVD risk in metabolically healthy with high VAI (MHHV), equivalent to MHO, was similar to its normal VAI counterpart, independent of gender (OR = 0.92, 95% CI 0.7-1.2, p = 0.55 for females; OR = 1.23, 95% CI 0.9-1.7, p = 0.25 for men). The study provides insights into ASCVD risk in multiple metabolic and obesity phenotypes among Saudi individuals, indicating that VAI outperforms BMI in identifying the metabolically healthy obese phenotype.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.